Lentigen is a diversified biologics company focused on the development and commercialization of breakthrough treatments for human disease. Lentiviral vectors (LV), the company's technology platform, are widely recognized by the scientific community as the most efficient method for delivery of genetic sequence information into cells to reprogram their function. The ability to efficiently and stably reprogram mammalian cells has numerous uses in biotechnology and biomedicine, including drug discovery, target validation, biologics manufacturing and cellular therapies.
Lentimax™:
Description:
LentiMax™ is a highly optimized HIV-based Lentiviral vector that can be engineered to express any gene or gene silencing RNA of interest. Lentigen uses LentiMax to build custom-made research-grade vectors.
Lentigen focus on custom manufacture of lentiviral vectors, users design their vector using an online tool where one simply clicks between the tabs to insert a gene, gene silencing sequence, promoter, post-transcriptional elements, and other options. The user cuts and pastes their own sequence into the appropriate fields or selects from the examples provided. Once finished, the user clicks the "checkout" tab to finalize their order. Lentigen then constructs, manufactures, and Quality Control tests the LV prior to shipment.
Lentigen's LentiMax Production System is designed for safe and optimized production of Lentiviral vectors. LentiMax and the LentiMax Production System have been engineered with numerous safety features to increase the safety of the vector system for translation into human clinical trials. Currently, LentiMax is licensed for research use only.
